Skip to main content
Premium Trial:

Request an Annual Quote

Personalis Taps Berry Genomics to Facilitate Expansion in China

NEW YORK – Personalis said on Wednesday that it is partnering with Berry Genomics to facilitate its expansion into China.

Personalis said that it plans to form a wholly owned subsidiary in Shanghai, including a laboratory for local customers to use its ImmunoID NeXT platform, a commercial team to support local customers, and general and administrative functions.

Under the terms of the agreement, Berry Genomics will provide Personalis with certain services and local support.

"Having achieved a high degree of scale in our Menlo Park, California operation, we are poised to expand globally, and entering into a partnership with a company that has the track record and capabilities of Berry Genomics will help us accelerate the ramp-up of our operation," Personalis CEO John West said in a statement. "Both companies have benefited from experience founded in the origin of next-generation sequencing, and together we will take it even further."

The ImmunoID NeXT platform leverages deep sequencing to enable researchers studying immune- and precision oncology to comprehensively analyze a tumor and its microenvironment from a single sample across the entire approximately 20,000-gene footprint.

Earlier this year Personalis launched a dedicated pharmaceutical services program to expand beyond its translational and clinical cancer research customer base.